Beneficial effects of the AT(2) receptor agonist buloxibutid (C21) against acute alveolar epithelial cell inflammation during antiviral responses.

Conforti F, Bell J, Ridley R, Dean L, Loxham M, Parkin J, Alzetani A, Jones MG, Dalsgaard CJ, Raud J, Davies DE

DOI: 10.1183/23120541.00249-2025
Published: 2026 Jul
Container: ERJ open research
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1183/23120541.00249-2025,
  title = {Beneficial effects of the AT(2) receptor agonist buloxibutid (C21) against acute alveolar epithelial cell inflammation during antiviral responses.},
  author = {Conforti F and Bell J and Ridley R and Dean L and Loxham M and Parkin J and Alzetani A and Jones MG and Dalsgaard CJ and Raud J and Davies DE},
  year = {2026},
  journal = {ERJ open research},
  doi = {10.1183/23120541.00249-2025},
  url = {https://doi.org/10.1183/23120541.00249-2025}
}

RIS

TY  - JOUR
TI  - Beneficial effects of the AT(2) receptor agonist buloxibutid (C21) against acute alveolar epithelial cell inflammation during antiviral responses.
AU  - Conforti F
AU  - Bell J
AU  - Ridley R
AU  - Dean L
AU  - Loxham M
AU  - Parkin J
AU  - Alzetani A
AU  - Jones MG
AU  - Dalsgaard CJ
AU  - Raud J
AU  - Davies DE
PY  - 2026
JO  - ERJ open research
DO  - 10.1183/23120541.00249-2025
UR  - https://doi.org/10.1183/23120541.00249-2025
ER  -

APA

F, C., J, B., R, R., L, D., M, L., J, P., A, A., MG, J., CJ, D., J, R., & DE, D. (2026). Beneficial effects of the AT(2) receptor agonist buloxibutid (C21) against acute alveolar epithelial cell inflammation during antiviral responses.. ERJ open research. https://doi.org/10.1183/23120541.00249-2025

Source records

pubmed · retrieved 2026-09-26T22:44:32.017Z